SCAR02
/ Siweikang Pharma, Anhui Provincial Hospital
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 16, 2024
An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases
(clinicaltrials.gov)
- P=N/A | N=18 | Recruiting | Sponsor: The First Affiliated Hospital of University of Science and Technology of China
CAR T-Cell Therapy • New trial • Immunology
1 to 1
Of
1
Go to page
1